Pulmonary Infections

Historical Context & Motivation

Pulmonary infections have been among the leading causes of morbidity and mortality throughout human history, and the study of pneumonia has driven some of the most transformative advances in microbiology, pharmacology, and public health. Hippocrates described pneumonia as a disease "named by the ancients" in 460 BCE, recognizing its clinical severity even before the germ theory of disease existed. The evolution from empirical observation to targeted antimicrobial therapy represents one of medicine's greatest achievements, yet lower respiratory tract infections remain the fourth leading cause of death globally and the leading infectious cause of death worldwide according to the World Health Organization. Understanding the historical arc of pulmonary infections illuminates why current diagnostic and treatment algorithms exist and highlights persistent clinical challenges, including antimicrobial resistance, immunocompromised hosts, and emerging pathogens.

Despite these advances, the fundamental clinical question persists: when a patient presents with fever, cough, and a pulmonary infiltrate, how does one systematically determine the causative organism, select appropriate empiric therapy, and recognize complications early enough to alter outcomes? This question drives every aspect of pulmonary infection education for clinical practice.

Core Principles & Classification

Pulmonary infections are broadly classified by the setting of acquisition, the immune status of the host, and the radiographic pattern of disease. These three axes allow clinicians to narrow the differential diagnosis and select empiric therapy rationally. Community-acquired pneumonia (CAP) is defined as pneumonia developing in a patient who has not been hospitalized within the preceding 90 days and was not residing in a long-term care facility. Hospital-acquired pneumonia (HAP) develops ≥ 48 hours after hospital admission, while ventilator-associated pneumonia (VAP) occurs ≥ 48 hours after endotracheal intubation. These distinctions are clinically critical because the likely pathogens differ dramatically between settings.

Visual Overview: Pneumonia Classification Algorithm

As shown in the diagram above, the classification begins at the broadest level with the setting of acquisition. Community-acquired pneumonia presents the widest differential but centers on Streptococcus pneumoniae as the single most common causative organism. Hospital-acquired and ventilator-associated pneumonias are dominated by multidrug-resistant organisms such as Pseudomonas aeruginosa, MRSA, and Acinetobacter baumannii. The green box at the bottom emphasizes that empiric therapy is a starting point—clinicians must narrow antibiotic coverage once culture and sensitivity data become available, typically within 48 to 72 hours. This principle of antibiotic stewardship is critical for reducing resistance and improving patient outcomes.

Pathogenesis & Severity Scoring

The pathogenesis of pulmonary infections involves a breach of the lung's elaborate defense mechanisms. Under normal conditions, the upper airway filters and humidifies inhaled air, the mucociliary escalator traps and propels particulates and microorganisms cephalad, and alveolar macrophages provide a final line of innate immune defense. Pneumonia develops when pathogen virulence overwhelms these defenses or when host defenses are compromised by factors such as smoking, aspiration, immunosuppression, or viral upper respiratory tract infection that damages the respiratory epithelium. Microaspiration of oropharyngeal flora is the most common mechanism for both CAP and HAP; less commonly, pneumonia results from hematogenous seeding (e.g., right-sided endocarditis causing septic pulmonary emboli), direct inhalation of environmental organisms (Legionella, Coccidioides), or contiguous spread from a pleural or mediastinal focus.

CURB-65 Severity Score

The CURB-65 score is a validated clinical prediction tool used to stratify severity in community-acquired pneumonia and guide disposition decisions. Each of the five criteria scores one point:

Organism-Specific Features & Radiographic Patterns

Identifying the causative organism in pulmonary infection relies on integrating clinical presentation, epidemiologic exposures, host factors, and radiographic patterns. While empiric therapy is initiated before definitive identification, certain classic associations are high yield for board examinations and clinical reasoning. The following table summarizes the most commonly tested organisms with their distinguishing features.

The radiographic patterns shown above are not pathognomonic for any single organism, but they substantially narrow the differential diagnosis when combined with clinical context. A young patient presenting with gradual-onset dry cough and bilateral interstitial infiltrates should prompt consideration of atypical pathogens, while an HIV-positive patient with a CD4 count below 200, subacute dyspnea, and bilateral ground-glass opacities on CT should immediately raise suspicion for Pneumocystis jirovecii pneumonia. The clinical correlation guide at the bottom of the diagram provides a rapid framework for linking radiographic patterns to clinical presentations during your initial assessment.

Worked Example: CAP Management

The following clinical vignette illustrates the systematic approach to evaluating and managing a patient presenting with community-acquired pneumonia, integrating history, physical examination, diagnostic workup, severity assessment, and treatment selection.

Empiric Antibiotic Regimens: Comparison & Limitations

Selecting the appropriate empiric antibiotic regimen depends on the clinical setting, severity of illness, local resistance patterns, and patient-specific factors such as allergies and comorbidities. The following table compares recommended empiric regimens for the major categories of pulmonary infection, along with their strengths and limitations.

Special Populations & Advanced Considerations

Several patient populations require special consideration when evaluating and managing pulmonary infections. The immunocompromised host represents the most clinically challenging scenario, as the differential diagnosis expands dramatically and empiric therapy must often cover organisms that would never cause disease in immunocompetent individuals. Understanding the specific type of immune defect—humoral, cellular, neutropenic, or combined—helps focus the differential. Patients with HIV/AIDS and CD4 counts below 200 cells/µL are at risk for Pneumocystis jirovecii pneumonia (PCP), while those with CD4 counts below 50 are susceptible to disseminated Mycobacterium avium complex (MAC) and CMV pneumonitis. Solid organ transplant recipients are at risk for CMV, Aspergillus, and Nocardia, with the timeline post-transplant guiding the most likely pathogen.

Looking forward, the landscape of pulmonary infections continues to evolve with the emergence of multidrug-resistant organisms, novel viral pathogens, and the expanding population of immunocompromised patients. Advances in molecular diagnostics—including multiplex PCR panels that can identify dozens of respiratory pathogens within hours—are transforming clinical practice by enabling earlier targeted therapy. Similarly, the development of new antibiotic classes (e.g., cefiderocol for resistant gram-negatives) and antiviral agents (e.g., nirmatrelvir/ritonavir for SARS-CoV-2) reflects ongoing efforts to stay ahead of microbial evolution.

Practice Problems

Pulmonary Infections — Summary